OPKO 8-K: third-quarter 2025 results release, guidance and call

Rhea-AI Filing Summary

OPKO Health (OPK) furnished an 8-K stating it issued a press release with operating and financial highlights for the quarter ended September 30, 2025. The release also explains how to access the company’s conference call covering third-quarter results and provides financial guidance. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and a copy of the press release is attached as Exhibit 99.1.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000094480900009448092025-10-292025-10-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

OPKO Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33528	75-2402409
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4400 Biscayne Blvd.
Miami, Florida				33137
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 305 575-4100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		OPK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended September 30, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the third quarter ended September 30, 2025, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of the Company dated October 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		OPKO Health, Inc.
		By:	/s/ Adam Logal
Date: October 29, 2025		Name:	Adam Logal
		Title:	Senior Vice President, Chief Financial Officer

FAQ

What did OPKO Health (OPK) announce in this 8-K?

It issued a press release with operating and financial highlights for the quarter ended September 30, 2025.

Which SEC item does this relate to for OPK?

It relates to Item 2.02 (Results of Operations and Financial Condition).

When was the press release issued by OPKO Health?

The company announced the press release on October 29, 2025.

Does the announcement include conference call details?

Yes. The press release includes information on how to access the conference call covering third-quarter results.

Does OPKO provide financial guidance in this update?

Yes. The press release states the company will provide financial guidance.

Is the information considered filed or furnished?

The information in Item 2.02 and Exhibit 99.1 is furnished, not filed.

What exhibits are included with the 8-K?

Exhibit 99.1 is the press release; Exhibit 104 is the Cover Page Interactive Data File.